AMILI, a precision gut microbiome firm, raises new funding led by East Ventures
AMILI, Southeast Asia’s first and only precision gut microbiome company, today announced that it has secured new funding from East Ventures, a pioneering sector-agnostic venture capital firm that has supported over 300 tech companies across Southeast Asia. This fund strengthens AMILI’s balance sheet, following the company’s series A funding in June 2022.
Nusantics raised seed funding from East Ventures
Nusantics is a technology company that focuses on applying advancements in genomics and microbiome research to fulfill consumer needs of a healthy yet sustainable lifestyle.